10x Genomics, Inc. Deferred Income Tax Expense (Benefit)
10x Genomics, Inc. (TXG) reported Deferred Income Tax Expense (Benefit) of -$1.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-07
- 10x Genomics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$310.00K, a 143.72% decline from fiscal 2024.
- 10x Genomics, Inc. deferred income tax expense (benefit) for fiscal 2024 was $709.00K.
- 10x Genomics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$447.00K, a 428.68% decline from fiscal 2022.
- 10x Genomics, Inc. deferred income tax expense (benefit) for fiscal 2022 was $136.00K.
| Period end | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|
| 2026-06-30 | -$1.43M 10-Q · filed 2026-08-07 | |
| 2025-12-31 | -$310.00K 10-K · filed 2026-02-13 | |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-07 | |
| 2024-12-31 | $709.00K 10-K · filed 2026-02-13 | |
| 2023-12-31 | -$447.00K 10-K · filed 2026-02-13 | |
| 2022-12-31 | $136.00K 10-K · filed 2025-02-13 | |
| 2021-12-31 | -$690.00K 10-K · filed 2024-02-15 | |
| 2020-12-31 | $82.00K 10-K · filed 2023-02-16 | |
| 2019-12-31 | -$6.00K 10-K · filed 2022-02-18 |